Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. We determined hepatitis B virus (HBV) suppression rates among 18 lamivudine (3TC)-experienced HBV-human immunodeficiency virus-coinfected adolescents after treatment with tenofovir disoproxil fumurate (TDF). At TDF initiation, their m...

Full description

Saved in:
Bibliographic Details
Main Authors: Aurpibul L., Lumbiganon P., Hansudewechakul R., Kanjanavanit S., Bunupuradah T., Kosalaraksa P., Taeprasert P., Puthanakit T.
Format: Journal
Published: 2017
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85007247655&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/40623
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-40623
record_format dspace
spelling th-cmuir.6653943832-406232017-09-28T04:10:34Z Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents Aurpibul L. Lumbiganon P. Hansudewechakul R. Kanjanavanit S. Bunupuradah T. Kosalaraksa P. Taeprasert P. Puthanakit T. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. We determined hepatitis B virus (HBV) suppression rates among 18 lamivudine (3TC)-experienced HBV-human immunodeficiency virus-coinfected adolescents after treatment with tenofovir disoproxil fumurate (TDF). At TDF initiation, their median age was 17.6 years, and duration of 3TC exposure was 7.3 years. Eleven patients (61%) achieved HBV DNA < 60 IU/mL after 48 weeks on TDF and 3TC which was similar to adult studies, although hepatitis B surface antigen loss or hepatitis B envelope antigen seroconversion did not occur. 2017-09-28T04:10:34Z 2017-09-28T04:10:34Z 4 Journal 08913668 2-s2.0-85007247655 10.1097/INF.0000000000001491 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85007247655&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/40623
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
description Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. We determined hepatitis B virus (HBV) suppression rates among 18 lamivudine (3TC)-experienced HBV-human immunodeficiency virus-coinfected adolescents after treatment with tenofovir disoproxil fumurate (TDF). At TDF initiation, their median age was 17.6 years, and duration of 3TC exposure was 7.3 years. Eleven patients (61%) achieved HBV DNA < 60 IU/mL after 48 weeks on TDF and 3TC which was similar to adult studies, although hepatitis B surface antigen loss or hepatitis B envelope antigen seroconversion did not occur.
format Journal
author Aurpibul L.
Lumbiganon P.
Hansudewechakul R.
Kanjanavanit S.
Bunupuradah T.
Kosalaraksa P.
Taeprasert P.
Puthanakit T.
spellingShingle Aurpibul L.
Lumbiganon P.
Hansudewechakul R.
Kanjanavanit S.
Bunupuradah T.
Kosalaraksa P.
Taeprasert P.
Puthanakit T.
Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents
author_facet Aurpibul L.
Lumbiganon P.
Hansudewechakul R.
Kanjanavanit S.
Bunupuradah T.
Kosalaraksa P.
Taeprasert P.
Puthanakit T.
author_sort Aurpibul L.
title Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents
title_short Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents
title_full Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents
title_fullStr Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents
title_full_unstemmed Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents
title_sort response to tenofovir among lamivudine-experienced hepatitis b and hiv-coinfected adolescents
publishDate 2017
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85007247655&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/40623
_version_ 1681421851671134208